Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

被引：16
|
作者：
Wang, Yang [1 ]
Li, Jingxin [2 ]
Wang, Yuxiao [1 ]
Gu, Wei [3 ]
Zhu, Fengcai [1 ,2 ]
机构：
[1] Southeast Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
[2] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期
关键词：
clinical trials; high-risk population; immunization strategy; pneumococcal polysaccharide vaccine; vaccine efficacy; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYOCARDIAL-INFARCTION; WORKING-AGE ADULTS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; MATERNAL IMMUNIZATION; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; CLINICAL EFFECTIVENESS; DISEASE EPIDEMIOLOGY;
D O I：
10.1080/21645515.2017.1409316
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people >= 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.
引用
收藏
页码：1003 / 1012
页数：10
相关论文
共 50 条
  • [1] Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly
    Kuo, Chia-Sheng
    Lu, Chia-Wen
    Chang, Yu-Kang
    Yang, Kuen-Cheh
    Hung, Shou-Hung
    Yang, Ming-Ching
    Chang, Hao-Hsiang
    Huang, Chi-Ting
    Hsu, Chih-Cheng
    Huang, Kuo-Chin
    MEDICINE, 2016, 95 (26)
  • [2] 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia
    Tanimoto, Tetsuya
    Kusumi, Eiji
    Hosoda, Kazutaka
    Hamaki, Tamae
    Takahashi, Kenzo
    LANCET INFECTIOUS DISEASES, 2017, 17 (07): : 692 - 693
  • [3] 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia
    Suzuki, Motoi
    Dhoubhadel, Bhim Gopal
    Katoh, Shungo
    Ariyoshi, Koya
    Morimoto, Konosuke
    LANCET INFECTIOUS DISEASES, 2017, 17 (08): : 803 - 804
  • [4] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in Navajo adults
    Benin, A
    O'Brien, K
    Watt, J
    Reid, R
    Zell, ER
    Katz, S
    Donaldson, C
    Parkinson, A
    Schuchat, A
    Santosham, M
    Whitney, CG
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1148 - 1148
  • [5] Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly
    Simonsen, V
    Brandao, AP
    Brandileone, MCC
    Yara, TI
    Di Fabio, JL
    Lopes, MH
    Jacob, W
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2005, 38 (02) : 251 - 260
  • [6] Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults
    Benin, AL
    O'Brien, KL
    Watt, JP
    Reid, R
    Zell, ER
    Katz, S
    Donaldson, C
    Parkinson, A
    Schuchat, A
    Santosham, M
    Whitney, CG
    JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (01): : 81 - 89
  • [7] Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska Native adults
    Singleton, Rosalyn J.
    Butler, Jay C.
    Bulkow, Lisa R.
    Hurlburt, Debby
    O'Brien, Katherine L.
    Doan, William
    Parkinson, Alan J.
    Hennessy, Thomas W.
    VACCINE, 2007, 25 (12) : 2288 - 2295
  • [8] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
    Masuda, Toshihiro
    Akamatsu, Taisuke
    Nakatani, Eiji
    Tamura, Kanami
    Takahashi, Shingo
    Tanaka, Yuko
    Watanabe, Hirofumi
    Endo, Yoshinari
    Suzuki, Takahito
    Noguchi, Rie
    Saigusa, Mika
    Yamamoto, Akito
    Shishido, Yuichiro
    Akita, Takefumi
    Morita, Satoru
    Asada, Kazuhiro
    Shirai, Toshihiro
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [9] Cost effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany
    Jiang, Yiling
    Gauthier, Aline
    Annemans, Lieven
    van der Linden, Mark
    Nicolas-Spony, Laurence
    Bresse, Xavier
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 645 - 660
  • [10] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Cornelius Remschmidt
    Thomas Harder
    Ole Wichmann
    Christian Bogdan
    Gerhard Falkenhorst
    BMC Infectious Diseases, 16
12345